Profile of agomelatine and its potential in the treatment of generalized anxiety disorder

Overview of attention for article published in Neuropsychiatric Disease and Treatment, May 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 6 tweeters
patent: 3 patents

facebook: 2 Facebook pages

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 33 Mendeley

Summary Twitter Patents Facebook Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

Suspected Agomelatine-induced restless legs syndrome: a case report

Article in BMC Psychiatry (April 2021)

Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies

Article in Advances in Therapy (February 2021)

Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders

Article in Pharmacology & Therapeutics (August 2019)